TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed/Refractory Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient had a previous diagnosis of multiple myeloma~* Patient required retreatment for multiple myeloma~* Patient had measurable M component in serum or urine at study screening~Exclusion Criteria:~* Primary refractory disease (patients that never reached at least an minor response for over 60 days under any prior therapy)~* Patient who had been treated by bortezomib before, and did not reach at least a minor response under this therapy, or progressed under it or within 60 days of last dose~* Patient received prior treatment with DAC inhibitors including panobinostat~* Patient had impaired cardiac function, or a prolonged QTc interval at screening ECG

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LBH589 + bortezomib + dexamethasone (Type: EXPERIMENTAL): Participants were administered LBH589 (panobinostat)in combination with bortezomib and dexamethasone 2 weeks on/1 week off.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Osteoporosis in Men With Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Men age 50-85~* Stage D0 prostate cancer~* On androgen deprivation therapy~Exclusion Criteria:~* Renal failure~* Hyperthyroidism~* Cushing's syndrome~* Metabolic bone disease~* Use of glucocorticoids~* Use of certain anticonvulsants~* On osteoporosis therapies~* Nonprostate cancers

- Gender: MALE
- Minimum Age: 50 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of rheumatoid arthritis~* Patients must be either DMARD naive or have failed at least one DMARD agent (e.g. MTX, leflunamide or sulfasalazine)~* Patients are allowed up to 3 DMARDs at study entry (e.g. MTX, sulfasalazine or hydroxychloroquine) as long as their dose was stable for 4 weeks prior to initiating study treatment~* Disease activity at screening defined by ≥6 out of 28 tender joints and ≥6 out of 28 swollen joints and hsCRP \>10mg/L~Exclusion Criteria:~* Patients with severe rheumatoid arthritis (functional status class IV according to the ACR 1991 revised criteria)~* Previous exposure to secukinumab or any other biologic, including TNF inhibitors.~* Use of high potency opioid analgesics~* Pregnant or nursing (lactating) women~* Use of any investigational drug other than RA therapy and/or devices at the time of randomization or within 30 days or 5 half-lives of randomization, whichever is longer.~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Secukinumab (Type: EXPERIMENTAL): 10 mg/kg intravenous (I.V.)
- Placebo (Type: PLACEBO_COMPARATOR): Placebo I.V.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacodynamics of Omiganan (CLS001) in Patients With Atopic Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Male and female subjects with mild to moderate AD 18 to 65 years of age, inclusive.~2. AD diagnosed by physician / medical specialist and that has been (intermittently) present for at least 1 year~3. Able to participate and willing to give written informed consent and to comply with the study restrictions.~Exclusion Criteria:~1. Have any current and / or recurrent clinically significant skin condition in the treatment area other than AD.~2. Any confirmed, active significant allergic reactions (urticaria or anaphylaxis) including allergic reactions against any drug, multiple drug allergies or (ingredients of) emollients.~3. Participation in an investigational drug or device study within 3 months prior to screening or more than 4 times a year.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- CLS001 topical gel, 2.5% (Type: EXPERIMENTAL): None
- CLS001 topical gel 1% (Type: EXPERIMENTAL): None
- Vehicle gel (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ultrasound Guided Pain Control Versus Standard Treatment in Emergency Department HIP Fracture Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. English speaking patients~2. ≥18 years of age~3. radiographic evidence of hip fracture~4. Patients must be awake, alert and oriented to time, place and person.~5. pain score of ≥ 5 in 10 point scale.~Exclusion Criteria:~1. cognitive deficits~2. allergic to amide-type local anesthetic or morphine~3. more injuries than just hip fracture.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- UFNB (Type: EXPERIMENTAL): Ultrasound guided 3 in 1 femoral nerve block: The UFNB was performed by first visualizing the femoral nerve in a transverse orientation just inferior to the inguinal ligament and lateral to the common femoral artery.
- UFIB (Type: EXPERIMENTAL): Ultrasound Guided Fascia Iliaca Compartment Block: For the UFIB, the two fascial planes, the fascia lata and the fascia iliaca, were sonographically visualized with the probe transverse to the thigh just inferior to the inguinal ligament and one-third of the distance from the anterior superior iliac spine to the pubic tubercle.
- IVMS (Type: ACTIVE_COMPARATOR): IV Morphine: IV Morphine patients were also monitored for a minimum of one hour after they were given a second dose of IV morphine, 0.1 mg/kg, once the radiographs demonstrated fracture. The control group was also eligible to receive rescue analgesia of an additional 0.1 mg/kg of IV morphine, followed by repeat doses of 0.05 mg/kg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Analgesic Effect of Different Combinations of Dexketoprofen Trometamol With Tramadol Hydrochloride in a Model of Moderate to Severe Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 10.0

Eligibility Criteria:
Inclusion Criteria:~Patients meeting ALL the following criteria will be eligible for entry into the study:~* Male or female patients aged 18 to 70 years old. Females participating in the study must be either: of non-childbearing potential, or willing to use a highly effective contraceptive method.~* Scheduled for outpatient surgical extraction -under local anaesthesia- of third mandibular molar teeth, with at least one of which is fully or partially impacted in the mandible requiring bone manipulation.~* Normal physical examination or without clinically relevant abnormalities.~At randomisation (after surgery):~No intake of analgesics (including prescription and over the counter drugs) within 24h prior to the surgery.~* No complication during the surgery, duration of surgery \< 1 hour and not requiring re-anaesthesia.~* Patients experiencing pain of moderate or higher intensity in the first four hours after the end of surgery.~Exclusion Criteria:~* History of allergy or hypersensitivity to NSAIDs, opioids or acetyl salicylic acid.~* History of asthma, bronchospasm, acute rhinitis, nasal polyps, urticaria or angioneurotic oedema.~* History of peptic ulcer, gastrointestinal disorders by NSAIDs, gastrointestinal bleeding or other active bleedings.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- Ibuprofen (Type: ACTIVE_COMPARATOR): None
- TRAM.HCl high dose (Type: ACTIVE_COMPARATOR): None
- TRAM.HCl low dose (Type: ACTIVE_COMPARATOR): None
- DKP-TRIS high dose (Type: ACTIVE_COMPARATOR): None
- DKP-TRIS low dose (Type: ACTIVE_COMPARATOR): None
- DKP-TRIS low dose - TRAM.HCl low dose (Type: EXPERIMENTAL): None
- DKP-TRIS low dose - TRAM.HCl high dose (Type: EXPERIMENTAL): None
- DKP-TRIS high dose - TRAM.HCl low dose (Type: EXPERIMENTAL): None
- DKP-TRIS high dose - TRAM.HCl high dose (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Zollinger-Ellison Syndrome With Prevacid

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with Zollinger-Ellison syndrome~Exclusion Criteria:~* Pregnant or lactating females

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- single group (Type: EXPERIMENTAL): This is an open label, non-randomized, uncontrolled, single group study designed to treat patients with Zollinger-Ellison Syndrome and other hypersecretory conditions by controlling gastric acid production; to heal and prevent relapses of peptic ulcers and symptoms; to monitor the safety and efficacy of this treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long-term Safety Study of BHV-3500 (Zavegepant*) for the Acute Treatment of Migraine

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 2-8 moderate to severe migraines/month within the last 3 months~* Migraine attacks present for more than 1 year with age of onset of migraines prior to 50 years of age~* Migraine attacks, on average, lasting about 4-72 hours if untreated~* Less than 15 days with headaches (migraine or non-migraine) per month in each of the 3 months prior to the screening visit~* Ability to distinguish migraine attacks from tension/cluster headaches~* Participants with contraindications for use of triptans may be included provided they meet all other study entry criteria~Exclusion Criteria:~* History of human immunodeficiency virus disease~* History of basilar or hemiplegic migraine~* Current diagnosis of major depressive disorder requiring treatment with atypical antipsychotics, schizophrenia, bipolar disorder, or borderline personality disorder~* History of nasal surgery in the 6 months preceding the screening visit~* History of gallstones or cholecystectomy~* History of gastric, or small intestinal surgery (including gastric bypass, gastric banding, gastric sleeve, gastric balloon, etcetera), or other disease or condition (for example, chronic pancreatitis, ulcerative colitis, etcetera) that causes malabsorption.~* Body mass index ≥ 33~* Hemoglobin A1c ≥6.5%

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Zavegepant (BHV-3500) (Type: EXPERIMENTAL): 10 mg intranasal (IN) up to 8 times per month, up to 1 year

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Cariprazine for Bipolar I Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who have provided informed consent prior to any study specific procedures~* Patients currently meeting the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria for bipolar I disorder, as confirmed by the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (SCID) manic or mixed type with or without psychotic symptoms~* Voluntarily hospitalized for current manic episode~* Patients with normal physical examination, laboratory, vital signs,and/ or electrocardiogram (ECG)~Exclusion Criteria:~* Patients with a DSM-IV-TR diagnosis of an axis I disorder other than bipolar I disorder that was the primary focus of treatment within the previous six months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Cariprazine (3-6 mg/day) (Type: EXPERIMENTAL): Cariprazine 3 milligrams (mg) - 6 mg capsules oral administration, once per day for 3 weeks.
- Cariprazine (6-12 mg/day) (Type: EXPERIMENTAL): Cariprazine 6 mg - 12 mg capsules oral administration, once per day for 3 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo dose-matching cariprazine capsules oral administration, once per day for 3 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Have haemophilia A or B with inhibitors to factor VIII or IX, respectively~* Have had a historical inhibitor level of at least five Bethesda units or have had an inadequate haemostatic response to 250 U/kg of factor VIII or IX or have had an inadequate response to FEIBA~* Require pre-planned major surgery in hospital~Exclusion Criteria:~* Have participated in or have been treated with any investigational drug other than activated recombinant human factor VII within the last thirty days~* Have been treated with any haemostatic agent, including rFVIIa, within 48 hours of preoperative dose~* Have any haemostatic disorder other than haemophilia

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Continuous infusion (Type: EXPERIMENTAL): None
- Bolus injection (Type: EXPERIMENTAL): None
- Control (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Completion of the treatment phase of the lead-in study, LAC-MD-31~* Written informed consent obtained from the patient before the initiation of any study specific procedures~* No medical contraindication as judged by the PI~* Compliance with LAC-MD-31 study procedures and IP dosing.~Exclusion Criteria:~* No specific exclusion criteria

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Aclidinium bromide/formoterol Fixed-Dose Combination (FDC) high dose
- 2 (Type: EXPERIMENTAL): Aclidinium bromide/formoterol Fixed-Dose Combination (FDC) low dose
- 3 (Type: ACTIVE_COMPARATOR): Aclidinium bromide 400 μg
- 4 (Type: ACTIVE_COMPARATOR): Formoterol Fumarate 12 μg
- 5 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Genetic Basis for Variation in the Renal Elimination of Metformin

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects have previously participated in the Study Of Pharmacogenetics In Ethnically Diverse Populations (SOPHIE) study.~* 18-40 years old~* Possess a pre-specified genotype for OCT2~Exclusion Criteria:~* Taking any regular medications other than vitamins.~* Individuals with anemia (hemoglobin \< 12 g/dL), an elevation in liver enzymes to higher than double the respective normal value, or elevated creatinine concentrations (males ≥ 1.5 mg/dL, females ≥ 1.4 mg/dL)~* Pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- OCT2-variant Group (Type: EXPERIMENTAL): Subjects with OCT2-variant genotype will be given a single oral dose of 850 mg of metformin.
- OCT2-reference Group (Type: EXPERIMENTAL): Subjects with OCT2-reference genotype will be given a single oral dose of 850 mg of metformin.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Postmenopausal Evaluation and Risk-reduction With Lasofoxifene (PEARL)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Postmenopausal at least 5 years; Screening bone mineral density more than or equal to 2.5 S.D.s below the mean for young adults at the lumbar spine or femoral neck.~Exclusion Criteria:~Metabolic bone disease other than osteoporosis; Taking approved medications for osteoporosis; Have had a recent osteoporotic fracture (within 1 year) and/or have a bone mineral density more than 4.5 S.D.s below the mean for young adults at the lumbar spine or femoral neck.

- Gender: FEMALE
- Minimum Age: 60 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- lasofoxifene 0.5 mg/day (Type: EXPERIMENTAL): None
- placebo (Type: PLACEBO_COMPARATOR): None
- lasofoxifene 0.25 mg/day (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Use of Protamine for Heparin Reversal After Catheter Ablation of Atrial Fibrillation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient's referred for radiofrequency ablation (RFA) or cryoablation for atrial fibrillation or atrial flutter (left atrial).~* Age ≥ 18 year~* Patients who are mentally and linguistically able to understand the aim of the trial, comply with the trial protocol, verbally acknowledge the risks, benefits, and alternatives in this trial.~Exclusion Criteria:~* Previous intolerance or allergy to heparin products.~* Current or prior administration of protamine products~* History of femoral access site complications including hematoma, AV fistula, pseudoaneurysm, aneurysm.~* Known lower extremity venous thrombosis.~* Coagulopathy or blood dyscrasias.~* Active malignancy.~* Thrombocytosis (platelet count \>600k/ul) or thrombocytopenia (platelet count \<100k/ul)~* Planned use of vascular closure device

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control (Type: NO_INTERVENTION): Patients in the control arm will undergo routine post-procedure management prior to removal of vascular sheaths. This includes routine measurements of ACT beginning 90 min after the cessation of the procedure with a goal ACT of \<200s or return to pre-procedural baseline prior to sheath removal.
- Protamine (Type: ACTIVE_COMPARATOR): Patients in the active comparator arm will receive protamine sulfate for rapid reversal of heparin prior to sheath removal. They will first receive a small test dose with close hemodynamic monitoring followed by therapeutic dose if no reaction occurs.ACT levels will then be monitored with a goal ACT of \<200s or return to preprocedural baseline prior to removal of vascular sheaths.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete